The seventh batch of national mining, the latest news

Today, Cyberblue confirmed by many parties that due to the epidemic, the progress of the seventh batch of national procurement has been postponed.

01The progress of the seventh batch of national procurement was delayed

A person familiar with the matter told Cyberland that the original plan for the seventh batch of national procurement was to release the centralized procurement documents before March.

The above-mentioned person further pointed out that if the centralized procurement documents are successfully released before March, according to the original arrangement, the seventh batch of national procurement will be able to enter the results release stage from April to May

As for the follow-up progress of centralized procurement, many industry insiders said that it is difficult to predict the continuous progress of the epidemic in Shanghai at this stage

The first 6 batches of national procurement were all organized by the Shanghai Alliance.

At present, the epidemic situation in Shanghai is still running at a high level, and the situation is extremely severe

As of 6:00 on April 5, 2022, Shanghai has 13 medium-risk areas

For the follow-up bid opening work of the seventh batch of national mining, some people in the industry think or adopt the form of online quotation

Indeed, looking back at the past few rounds of national procurement, strict personnel entry and exit and signal control were carried out during the quotation period, which was also to ensure the fairness and impartiality of the bid opening process

In fact, in the context of centralized procurement encountering the epidemic, epidemic prevention and control has become an issue that participating companies must continue to pay attention to - the third/fourth/fifth/sixth batch of centralized procurement documents stipulates, "According to the normalized epidemic situation According to the prevention and control requirements, those who have a history of living in medium and high-risk areas in the 14 days before the disclosure of the declaration information shall not participate in the declaration as enterprise representatives

02 Does not rule out new changes

According to Cyberlane, it has been nearly 3 months since the seventh batch of Guocai was circulated from the catalogue

The seventh batch of national harvests includes a total of 58 varieties, of which 28 are injections, involving a market size of 35 billion yuan, and about 18 large varieties exceeding 1 billion - such as oseltamivir, afatinib, and metor.

According to relevant statistics, as of now, there are about 200 pharmaceutical companies that meet the conditions for participation, including 29 foreign companies

After sorting out Cyberland, it was found that on January 21, the industry began to circulate the seventh batch of centralized procurement catalogues; Ningxia, Shanxi, Sichuan and other places issued documents announcing that the seventh batch of national procurement was launched on January 26 and reported on February 16.

Since February 18, there has been no official progress in the seventh batch of national mining

According to the regular progress of procurement with volume, after the procurement demand is reviewed and reported (after February 25), it will enter the stages of announcement of centralized procurement documents, opening of bids, announcement of the proposed selection results, confirmation of the official selection results and landing time
.

At present, for the seventh batch of national procurement, in addition to the covered varieties and basically stable quotation rules, the competition pattern and more detailed rules are still uncertain
.

The above-mentioned people told Cyberland that in fact, every time the national procurement rules have been slightly updated, specifically to the seventh batch of national procurement, in addition to the 1+3 principle circulated before, there is also news that the supply province of the selected enterprises may change - by One company in each province is selected, and it is changed to more than one supply company in each province
.

If the above rules come true, the importance of guaranteed supply is further enhanced
.
In fact, while the national procurement is normalized and the coverage is accelerated, quality and supply have indeed become the most frequently cited issues by the Shanghai Alliance
.

For more than 3 years, according to the statistics of Cyberblue, a total of 3 varieties and 3 companies have supply and quality problems after being selected - respectively, Celgene Corporation's paclitaxel for injection (albumin-bound), North China Pharmaceutical's cloth.
Proprofen Sustained-Release Capsules and St.
Francis Xavier's Glimepiride Tablets
.

When the supply of a single enterprise is not timely, the contradiction between supply and demand of medical institutions in individual provinces is prominent
.

The current procedure for confirming the supply provinces of the selected enterprises for national procurement is as follows: the enterprises select the supply regions in turn according to their respective positions, one at a time, until all regions are selected and confirmed
.
Except for the serious breach of trust and non-performance of the contract by the selected enterprise in the selected province, the selected province cannot refuse to be selected
.

03 Changes and changes in centralized procurement rules

Up to now, the rules for the centralized procurement of five batches of chemical drugs have been steadily participated in the whole country, and a maximum of 10 companies are allowed to be shortlisted, as follows:

Meeting one of the three conditions of a 1.
8-fold circuit breaker mechanism, a drop of 50% or more, and a unit comparable price of less than or equal to 0.
1 yuan is still a condition for an enterprise to obtain the qualification to be selected
.

Nationwide participation, a maximum of 10 companies are allowed to be selected, and the procurement cycle of the varieties selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 companies and more, 3 years), 4 companies and 80% of the agreed purchase volume selected above (50% from 1, 60% from 2, and 70% from 3)
.

From December 2018 to now, the national centralized procurement has carried out five batches of chemical drugs, and 218 varieties have been selected.
The average decline is at least 50%, the largest is 59%, and the highest decline is more than 90%
.

The rule setting of centralized procurement generally revolves around the dimensions of price drop, product supply, and enterprise qualification
.

Judging from the practice of the previous batches, the bidding rules have been relatively stable because of their effectiveness, and the rules for ensuring supply are being continuously optimized— increasing the number of selected companies; strengthening the application of violation lists and untrustworthy ratings in the field of centralized drug procurement; implementing alternative mechanisms (When the selected enterprise is unable to supply the procurement needs of medical institutions in time, the province where it is located can initiate the selection process of the alternative enterprise)
.

A few days ago, Chen Jinfu, deputy director of the National Medical Insurance Administration, also pointed out that in the past, purchasing with quantity was the "moisture" that quickly squeezed the price of drugs, and there was a certain phenomenon of "low price priority", which also led to some companies bidding blindly.
Depression and sudden pressure on production capacity, there is a supply outage
.

Chen Jinfu emphasized that purchasing with quantity does not pursue the lowest price, and also firmly opposes running bidding.
The design of the rules is to achieve reasonable price adjustment and fair competition among enterprises
.

On January 10 this year, the National Standing Committee proposed that by the end of this year, the total number of national and provincial centralized procurement of drugs in each province will reach more than 350
.
At the regular policy briefing on February 11, Chen Jinfu further clarified that this year, he will guide the localities to make progress in accordance with clinical needs, focusing on large varieties and common diseases, to check and fill gaps, and strive to achieve provincial-level centralized collection of varieties carried out in each province.
reach more than 100
.

In the short-term, the centralized procurement will require two batches a year.
In the long-term, by 2025, the number of drugs to be purchased in a centralized manner will reach 500.
Considering the impact of sudden factors such as the epidemic, pharmaceutical companies still need to grasp the progress of the centralized procurement.
with possible changes
.

Attachment: The scope of the seventh batch of national procurement and the competition pattern of pharmaceutical companies (as of April 2)

The competition pattern of the seventh batch of products of national mining